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Myeloproliferative neoplasms (MPNs) are a heterogeneous group
of clonal haematopoietic stem cell disorders characterised by
proliferation and maturation of different myeloid cell lineages.
Classical MPNs are largely characterised by somatic mutation of
JAK2, CALR or occasionally MPL genes.1,2 MPNs can develop from
chromosomal translocations forming gene fusions, involving
constitutive activation and aberrant expression of tyrosine kinase
(TK). Other than the BCR-ABL1 rearrangement in chronic myeloid
leukaemia, gene fusions involving TK proto-oncogenes are rare in
MPN but when detected, provide compelling disease-specific
therapeutic targets.3 Myeloproliferative and lymphoid neoplasms
with eosinophilia and specific TK gene fusions are a recently
described, rare entity of clinical significance due to varying
responsiveness to tyrosine kinase inhibitors (TKIs).4 The three
cytogenetic categories identified, involving fusions of PDGFRA,
PDGFRB or FGFR1 with different partner genes, are thought to
affect a pluripotent stem cell and have variable presentation
as MPN with eosinophilia, occasionally with a T-lymphoid disease
component. Excellent response rates and long-term clinical
outcomes have been reported with abnormalities of PDGFRA
and PDGFRB treated with imatinib, whereas disorders with FGFR1
and JAK2 gene fusions are resistant to imatinib and other TKIs. We
present a case of a disease fitting within this clinical and
haematological spectrum, with a chromosomal rearrangement
between chromosomes 8 and 12, bearing ETV6–LYN gene fusion.
A 46-year-old man, of Bangladeshi origin, presented with a
3-month history of progressive swelling in his groin from bilateral
inguinal lymphadenopathy, associated with lethargy and sweats.
Histology from an excision biopsy of a left-sided inguinal node
diagnosed a precursor T-lymphoblastic lymphoma (T-LBL; CD2+,
CD3+, CD5+, CD10− , CD20+, focal weak CD79a, strong nuclear
Tdt +ve, cyclin D1− , bcl2 weak, bcl6− , Ki67 80% proliferative
fraction). Peripheral blood showed a leuco-erythroblastic picture
with high white blood cell count (17.2 × 109/l) with eosinophilia.
Bone marrow (BM) aspirate and trephine biopsies showed
prominent myeloid hyperplasia with eosinophilia, no excess of
blasts but with a 10% interstitial infiltrate of T-cell lymphoma. The
patient received dexamethasone, daunorubicin, vincristine and
asparaginase (UKALLXII trial regime), which eradicated the
lymphoma, but failed to control the myeloproliferative compo-
nent. Reinduction with FLA–IDA (fludarabine, high-dose cytara-
bine and idarubicin) reduced the WCC, but did not achieve
complete cytogenetic remission (see below). After approximately
5 months, the disease progressed to refractory acute myeloid
leukaemia (AML) and the patient died 7 months from first
presentation.
G-banded cytogenetic analysis of the diagnostic BM aspirate
showed an apparent translocation between the long arm of
chromosome 8 and short arm of chromosome 12, although the
resolution was not sufficient to confidently confirm the breakpoint
on chromosome 8 (Figure 1a). The majority of cells also showed
one or two additional copies of the derivative chromosome 8.
Fluorescence in situ hybridisation (FISH) using ETV6 gene probes
(Vysis, Downer’s Grove, IL, USA) showed ETV6 gene rearrangement
in 88/100 fixed cells from the BM aspirate and from a paraffin-
embedded tissue section from the lymph node infiltrated with
T-LBL, indicating a clonal relationship between the two tissues of
different morphology (Figures 1b and c). FISH with ETV6 gene
probes showed a normal signal pattern in cells from a buccal
smear and was also normal on BM cells using BCR-ABL1, KMT2A,
PDGFRA, PDGFRB and FGFR1 probes (Vysis). Reverse transcriptase
PCR showed no evidence of ETV6–NCOA2 gene rearrangement,
initially thought to be a candidate ETV6 fusion partner.5 DNA from
presentation BM and a sample during morphological remission
were hybridised to Affymetrix Genome-Wide Human SNP Array 6.0
(Affymetrix, Santa Clara, CA, USA), and copy number variation was
compared (Supplementary Figure 3a). Owing to the chromosome
imbalance from the additional copies of the abnormal chromo-
somes 8, the segments involved in the translocation were
demonstrated as DNA copy number change and the breakpoints
were defined in detail. Despite the presence of a recognisable
breakpoint within ETV6 on chromosome 12, the most distal break
on chromosome 8 was not within the open reading frame of a
recognised gene (Supplementary Figure 3b). Sites of deletion and
amplification of DNA sequences suggested greater molecular
disruption of the region and possibly implicated localised
chromothrypsis on chromosome 8. The LYN TK gene was found to
be at the border of a deletion of ~46 kb at 8q12.1 (Supplementary
Figure 4). An ETV6–LYN gene fusion was confirmed by RT-PCR using
primers as previously published6 (Supplementary Method 1 and
Figure 5) and capillary sequencing of the PCR product defined the
molecular junction (Supplementary Figure 6). This suggested a
complex chromosomal rearrangement comprising of at least three
breaks. In its simplest possible form, a 22.13 Mb inversion was
implicated (between positions 56 864 550 and 78 992 979 bp human
genome assembly hg19 on chromosome 8, flanked by deletions of
~46 kb at 8q12.1 and ~167kb at 8q21.1). This brings LYN and ETV6
into juxtaposition in the correct 5′–3′ orientation to create the in-
frame chimaeric fusion gene on the derived chromosome 8 and is
necessary owing to the opposite orientation of the genes to their
centromeres (Supplementary Figure 7).
The transforming potential of ETV6–LYN gene fusion in
haematological malignancy has been demonstrated previously
from a study screening artificially constructed ETV6 fusion partners
from complementary DNA.7 However, there is only one previous
clinical case report of ETV6–LYN fusion gene, with myelofibrosis,
resulting from an interchromosomal insertion, ins(12;8)(p13;
q11q21), again demonstrating that a three-break rearrangement
is required for the fusion to form.8 The genomic breakpoints in the
current case yield a chimaeric mRNA with fusion of exons 5 in
ETV6 to exon 8 in LYN, identical to the previous report. As multiple
breaks are required to create the reported fusion, it may explain
why the rearrangement appears rare, but also suggests that some
chromosomal rearrangements may be cryptic and that ETV6–LYN
may be underreported. One further case of eosinophilic MPN/T-
LBL with t(8;12), but without confirmation of ETV6–LYN, shows
remarkably similar clinical features to the current case.9 All three
patients were young adult males, with a myeloproliferative disease
in the BM, two having peripheral T-LBL. All three patients were
refractory to intensive chemotherapy or stem cell transplant and
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showed a rapid progression to terminal AML (Supplementary
Table 1). Patients with the fusion appear to be desperate
candidates for novel approaches to treatment in attempt to
improve outcomes.
ETV6 (ets variant 6, formerly TEL) encodes a ubiquitously expressed
nuclear protein, acting as a signal-dependent transcription repressor,
mediating cell proliferation and differentiation, and is necessary for
the maintenance of haematopoiesis of all cell lineages. ETV6 is
recognised as having an important role in leukaemogenesis through
different oncogenic mechanisms, including the formation of gene
fusions with up to 30 partner genes.10 ETV6 partners with non-
receptor TK genes, in which fusion typically occurs at exon 4 or 5 of
ETV6, with retention of the activating helix-loop-helix oligodimersa-
tion (pointed (PNT)) domain and the TK functionality of its partner.11
LYN (v-yes-1 Yamaguchi sarcoma viral related oncogene homologue,
formerly JTK8) is one of nine members of the Src family of
membrane-associated, non-receptor TKs, which fulfils a critical role in
the proliferative response of neoplastic myeloid cells to cytokine
signalling. LYN contains kinase (SH1), Src homology (SH2 and SH3)
and unique (SH4) domains.12 The ETV6–LYN gene fusion is typical of
the non-receptor TK translocations in that the PNT domain of ETV6
activates LYN by protein oligomerization and autophosphorylation of
the kinase, stimulating STAT3 and STAT5, resulting in neoplastic
transformation to myeloproliferative disease, independent of
upstream JAK2 activation.6
Lyn is consistently expressed in AML13 and in imatinib-resistant
chronic myeloid leukaemia,14 and is therefore a compelling
pharmacologic target for leukaemia therapy. Inhibition of Lyn
kinase activity has been demonstrated using Src kinase inhibitors,
resulting in control of STAT5 activation with induction of apoptosis
and suppression of leukaemic cell growth. The presence of ETV6–
LYN may offer a valid biomarker predicting sensitivity of the
disease to TKI. The single previous case of ETV6–LYN was
insensitive to imatinib clinically8 and experimentally sensitive to
dasatinib.6,8 We investigated the in vitro sensitivity to dasatinib,
imatinib, bosutinib and nilotinib in a series of experiments on
fresh-frozen, stored cells from the patient’s BM at diagnosis and in
morphological remission as control (Methods, see Supplementary
Material 5). The patient’s diagnostic marrow cells appeared to
have erythroid burst-forming units growing independently of
cytokines, in keeping with an MPN. The primary cells from the
diagnostic marrow showed increased sensitivity to dasatinib
compared with the remission marrow (Figure 2a), which is
consistent with previous observations. A response to imatinib
Figure 1. (a) G-banded karyogram from the diagnostic bone marrow showing the rearrangement between the long arm of chromosome 8
and short arm of chromosome 12 (arrowed), with an extra copy of the derivative chromosome 8, International System for Human Cytogenetic
Nomenclature (ISCN) karyotype refined as: 46,XY,der(8)inv(q12.1q21.1)t(8;12)(q12.1;p13),der(12)t(8;12)(q12.1;p13)[2]/47,sl,+der(8)inv(8)t(8;12)[5]/48,
sdl1,+der(8)inv(8)t(8;12)[2]/46,XY[2]. Fluorescence in situ hybridisation (FISH) with ETV6 break apart gene probes showing split red and green signals,
and extra red signal from the duplicated der(8) in interphase cell nuclei from the bone marrow aspirate (b) and on the paraffin-embedded tissue
section from the lymph node biopsy (c).
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was also apparent, whilst there was no observed benefit of using
nilotinib and bosutinib (Figures 2a and b). Sensitivity of cells from
the diagnostic BM to various concentrations of dasatinib (0.1, 1
and 10 μM) showed that there was a significant effect at all doses
compared with remission and untreated cells, but that there was
no significant difference between different concentrations
(Figure 2b and Supplementary Information; Figure 8) and so no
dose–response relationship was apparent. Dasatinib is a small
molecule, spectrum TKI, known to inhibit the Src family kinases,
including Lyn, as well as Abl1 and receptor TKs, and this result was
expected. The superiority of dasatinib over bosutinib, a known Src
inhibitor, is unclear but could result from the broader spectrum of
dasatinib targeting co-expressed Src kinases having homology
with LYN, leading to combined inhibition of other interconnected
Figure 2. Charts showing relative cell death (data are arbitrary fluorescence units, double normalised by dividing by the maximum death unit
and then expressed relative to the untreated), measured over 72 h at the maximum concentration of TKI (a) and at different concentrations of
TKI (nM) (b). The patient’s diagnostic BM cells (black curve) show varying sensitivity to the TKIs, imatinib, dasatinib, nilotinib and bosutinib
compared with the remission marrow (grey curve).
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signalling pathways. Nilotinib and imatinib have similar selectivity
profiles and do not inhibit Src kinases. The previous evidence of
in vitro failure of imatinib therapy and repeated experimental
evidence of cell sensitivity to dasatinib makes this TKI a more
attractive candidate therapy for this disease, as a single agent or
with chemotherapy to enhance sensitivity.15
In summary, MPN with eosinophilia and T-LBL, involving
rearrangement of chromosomes 8 and 12 resulting in ETV6–LYN
gene fusion, is a rare entity consistent with the World Health
Organization category of myeloproliferative and lymphoid neo-
plasms with eosinophilia and specific gene fusions. On the basis of
the three available cases, this represents a high-risk disease with
fibrotic tendency, resistance to conventional therapy and rapid
progression to AML. Such patients may benefit from dasatinib
monotherapy or as an adjunctive therapy with conventional
cytotoxics.
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